Aphios® Corporation has been self-funded to date with Founders’ capital, employee stock ownership, grants and contracts from the National Institutes of Health and other institutions, collaborative and contract research with emerging biotechnology and multinational companies, and product sales to biotechnology companies and research chemical distribution houses, such as Millipore Sigma-Aldrich.  We are actively seeking investors and strategic corporate partners for:

• Aphios Pharma LLC which is developing cannabis-based, FDA approved drugs for opioid addiction, chemotherapy induced peripheral neuropathic pain (CIPNP) and other central and peripheral nervous system disorders

• Aphios International which is developing a green pathogen inactivation technology, CFI (critical fluid inactivation) for the clearance of viruses and other pathogens from biologics such as human plasma, human plasma products, and monoclonal antibodies